<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-9-21</article-id><article-id pub-id-type="pmid">18366797</article-id><article-id pub-id-type="doi">10.1186/1471-2350-9-21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Influence of leukotriene gene polymorphisms on chronic rhinosinusitis</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Al-Shemari</surname><given-names>Hasan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alshemari_q8@yahoo.ca</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Boss&#x000e9;</surname><given-names>Yohan</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>yohan.bosse@crhl.ulaval.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hudson</surname><given-names>Thomas J</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I5">5</xref><email>tom.hudson@oicr.on.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Cabaluna</surname><given-names>Myrna</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>myrna.cabaluna@muhc.mcgill.ca</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Duval</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mduval9@po-box.mcgill.ca</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Lemire</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I5">5</xref><email>mathieu.lemire@oicr.on.ca</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Vallee-Smedja</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>sophie_smejda@yahoo.ca</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Frenkiel</surname><given-names>Saul</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sfrenkie@ent.jgh.mcgill.ca</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Desrosiers</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I6">6</xref><email>desrosiers_martin@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC, Canada</aff><aff id="I2"><label>2</label>McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada</aff><aff id="I3"><label>3</label>Centre de Recherche, H&#x000f4;pital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l'Universit&#x000e9; Laval, Qu&#x000e9;bec, QC, Canada</aff><aff id="I4"><label>4</label>Laval University Hospital Research Center (CRCHUL), Quebec, QC, Canada</aff><aff id="I5"><label>5</label>Ontario Institute for Cancer Research, Toronto, ON, Canada</aff><aff id="I6"><label>6</label>Department of Otolaryngology-Head and Neck Surgery, Montreal University, Montreal, QC, Canada</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2008</year></pub-date><volume>9</volume><fpage>21</fpage><lpage>21</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/9/21"/><history><date date-type="received"><day>9</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Al-Shemari et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Al-Shemari et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Al-Shemari Hasan alshemari_q8@yahoo.ca </dc:author><dc:title> Influence of leukotriene gene polymorphisms on chronic rhinosinusitis </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 9(1): 21-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2008)9:1&#x0003c;21&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Chronic rhinosinusitis (CRS) is increasingly viewed as an inflammatory condition of the sinonasal mucosa interacting with bacteria and/or fungi. However, factors conferring susceptibility to disease remain unknown. Advances in genomics offer powerful tools to explore this disorder. The goal of this study was to evaluate the effect of single nucleotide polymorphisms (SNP) on CRS in a panel of genes related to cysteinyl leukotriene metabolism.</p></sec><sec sec-type="methods"><title>Methods</title><p>Severe cases of CRS and postal code match controls were recruited prospectively. A total of 206 cases and 200 controls were available for the present study. Using a candidate gene approach, five genes related to cysteinyl leukotriene metabolism were assessed. For each gene, we selected the maximally informative set of common SNPs (tagSNPs) using the European-derived (CEU) HapMap dataset. These SNPs are in arachidonate 5-lipoxygenase (ALOX5), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), leukotriene C4 synthase (LTC4S), cysteinyl leukotriene receptor 1 (CYSLTR1) and cysteinyl leukotriene receptor 2 (CYSLTR2) genes.</p></sec><sec><title>Results</title><p>A total of 59 SNPs were genotyped to capture the common genetic variations within these genes. Three SNPs located within the ALOX5, CYSLTR1 and ALOX5AP genes reached the nominal p-value threshold (p &#x0003c; 0.05) for association with CRS. However, none of these SNPs resist multiple testing adjustment.</p></sec><sec><title>Conclusion</title><p>While these initial results do not support that polymorphsims in genes assessed involved in the leukotriene pathways are contributing to the pathogenesis of CRS, this initial study was not powered to detect polymorphisms with relative risk of 2.0 or less, where we could expect many gene effects for complex diseases to occur. Thus, despite this lack of significant association noted in this study, we believe that validation with external populations and the use of better-powered studies in the future may allow more conclusive findings.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Chronic rhinosinusitis (CRS) is a frequent and important chronic disease, which causes significant patient discomfort and morbidity. Patients with CRS report a significantly lower quality of life index in measures of bodily pain and social functioning than do patients with congestive heart failure, angina, chronic obstructive pulmonary disease, and back pain [<xref ref-type="bibr" rid="B1">1</xref>]. In health surveys, CRS affect more than 10% of individuals in western countries, with an overall direct cost of CRS in the United States annually estimated at $4.3 billion [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Despite the frequency of CRS and the costs associated with its care, there is limited knowledge about the initial development of disease. Our current conception of CRS is as of a chronic inflammation of the paranasal sinus membrane, which is colonised with nasal and exogenous bacteria that may contribute to the disorder. Histologically, CRS is characterized by an accumulation of inflammatory cells that are mainly eosinophils, with a neutrophilic infiltrate only during acute infections. Numerous pro-inflammatory cytokines and chemokines, both Th-1 and Th-2 profiles, are over expressed in CRS. These include IL-2, IL-4, IL-5, IL-6, IL8, IL-13 and IL-16 [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Current knowledge of the disease is limited to that garnered by study of biopsy samples obtained from patients affected with well-established disease, with little information available on early events or environmental factors associated with development of disease. Genetic studies may thus offer a better insight into the pathogenesis of the disorder. Recently, the primary interest in genetics has changed from simple Mendelian diseases, for which genotypes of some gene are the cause of disease, to more complex diseases, for which genotypes of some set of genes together with environmental factors merely alter the probability that an individual gets the disease, although individual factors are typically insufficient to cause the disease outright [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Reports of familial clustering of CRS support a genetic basis for the disease [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. The high prevalence of patients with CRS in well-defined genetic disorders such as cystic fibrosis (CF) and primary cilia dyskinesia (Kartagener's syndrome) also supports the concept that mutated genes play a role in the pathogenesis of the disease [<xref ref-type="bibr" rid="B9">9</xref>]. However, it is suspected that CRS generally encountered in clinical practice is due to a complex interaction of multiple genes rather than the single gene anomalies as observed in CF and Kartagener's syndrome. A polygenic model for nasal polyps was recently confirmed by segregation analysis [<xref ref-type="bibr" rid="B10">10</xref>]. The same study also confirms that nasal polyp is a highly heritable disease with heritability coefficients above 60%. Interestingly, the quantitative contribution of genetic factors seems to be higher in young and recurrent patients [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. A number of genetic association studies have been conducted to elucidate the genetic loci conferring risk of CRS with or without nasal polyposis. Significant difference in allele frequencies between patients and controls were observed for polymorphisms located in the HLA [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>], CFTR [<xref ref-type="bibr" rid="B15">15</xref>], LTA [<xref ref-type="bibr" rid="B16">16</xref>], TGFB1 [<xref ref-type="bibr" rid="B17">17</xref>], IL1RN [<xref ref-type="bibr" rid="B18">18</xref>], and ADRB2 [<xref ref-type="bibr" rid="B19">19</xref>]. However, all these findings remain to be confirmed in larger populations.</p><p>It is possible that cysteinyl leukotrienes (cysLTs) may play a disease-regulating role in rhinosinusitis. CysLTs, described primarily as lipid mediators involved in pathogenesis of airway inflammation and related symptoms such as bronchoconstriction, mucus secretion, and airway hyperresponsiveness, are recognized now as important mediators of cell trafficking and innate immune responses [<xref ref-type="bibr" rid="B20">20</xref>]. CysLTs are synthesized through the lipoxygenase (LO) pathway of arachidonic acid metabolism. The LO pathway for synthesizing cysLTs has several steps, and distinct enzymes are involved in each steps, namely arachidonate 5-lipoxygenase (ALOX5), arachidonate 5-lipoxygenase-activating protein (ALOX5AP or FLAP), and leukotriene C4 synthase (LTC4S) [<xref ref-type="bibr" rid="B21">21</xref>]. Effects at the cellular level are mediated via two G-protein coupled receptors termed cysteinyl leukotriene receptor 1 (CYSLTR1) and cysteinyl leukotriene receptor 2 (CYSLTR2) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Arachidonic acid metabolism. Candidate genes selected for genotyping are indicated along the cysteinyl leukotriene metabolic pathway. LO, lipoxygenase pathway; COX, cyclo-oxygenase pathway; ALOX5, arachidonate 5-lipoxygenase; ALOX5AP, arachidonate 5-lipoxygenase-activating protein; LTC4S, leukotriene C4 synthase; CYSLTR1, cysteinyl leukotriene receptor 1; CYSLTR2, cysteinyl leukotriene receptor 2. Cysteinyl leukotriene metabolites are leukotriene B4 (LTB4), leukotriene C4 (LTC4), leukotriene D4 (LTD4), and leukotriene E4 (LTE4).</p></caption><graphic xlink:href="1471-2350-9-21-1"/></fig><p>In this initial study, we propose to study the genes regulating the leukotriene pathway to identify potential polymorphisms involved in disease susceptibility. We hope that identification of genetic polymorphisms involved will lead to improved comprehension of disease pathogenesis, and may eventually lead to more effective treatment, screening, and prevention of CRS.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Population</title><p>210 individuals with severe CRS were prospectively recruited from three tertiary rhinology clinics from July 2005 to February 2006. Four were not included in the final analysis, as phenotypic questionnaires were incomplete, leaving 206 subjects for analysis. These were compared to 200 control subjects. The study was approved by the McGill University Health Centre ethics committee, and written informed consent was obtained from all participants.</p><p>Subjects with sever CRS were recruited from ongoing clinical activities, according to pre-established clinical criteria. Severe CRS was defined as 1) individuals with persistent signs and symptoms of CRS with one previous endoscopic sinus surgery for diagnosis of either chronic rhinosinusitis with or without sinonasal polyposis or recurrent acute sinusitis or 2) individuals with more than one surgery for these diagnoses, regardless of outcome.</p><p>A standardized questionnaire assessing age, sex, ethnic origin, and family history was obtained. Other associated factors include smoking, presence of self-reported seasonal and perennial allergies, physician diagnosed asthma and acetylsalicylic acid intolerance were also obtained. Information on disease related factors including age at diagnosis, age at first surgery, number of previous surgeries, medications and current symptoms were determined. Initial diagnoses were obtained from patients records, and classified according to 2004 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines [<xref ref-type="bibr" rid="B22">22</xref>]. Diagnosis of aspirin sensitivity was based on a medical history reporting symptoms including asthma exacerbation, rhinorrhea, and nasal congestion, after the ingestion of aspirin or other nonsteroidal anti-inflammatory drugs. Four tubes of blood were drawn from patients with severe CRS. Two were for DNA extraction and the others were for the measurements of serum eosinophilia and total IgE. Blood samples were stored at -20 degrees Celsius for 2 days then at -80 degrees Celsius prior to use.</p><p>The control population was recruited from either patient's spouse or non-blood relatives living in the same household or by random telephone screening matched to affected subject's postal code. For the 30 spouse or non-blood relative controls, whole blood was used. In the 170 control subjects recruited by telephone screening, the Oragene kit (DNA Genotek, Ottawa, Ontario) for saliva collection was sent to the control subject with prepaid return postage. Saliva samples were stored at room temperature as recommended by the manufacturer.</p></sec><sec><title>IgE and eosinophilia measurements</title><p>Blood samples for total serum IgE and eosinophilia were processed by the hospital laboratory according to standard methods. Eosinophilia was reported as percent of total circulating white blood cells. IgE was reported in IU, with the upper range of normal reported as 120 IU/ml.</p></sec><sec><title>DNA extraction</title><p>DNA was isolated from peripheral blood leukocytes, collected in citrate-treated tubes, using the Puregene DNA isolation kit, (Gentra System, QIAGEN) following the High Throughput Protocol for 10 ml Whole Blood provided with this kit. DNA extracted from saliva was performed using the Oragene DNA Purification Protocol (DNA Genotek, Ottawa, Ontario). Isolated DNA from both blood and saliva was stored at -20 degrees Celsius prior to use.</p></sec><sec><title>SNP selection and genotyping</title><p>SNPs were selected to capture as much information as possible about genetic variation for each gene. That was achieved using the European-derived (CEU) genotype data from the International HapMap project [<xref ref-type="bibr" rid="B23">23</xref>] covering ten kilobases up- and downstream of each gene. From this dataset, a maximally informative set of SNPs were selected for each gene using an aggressive tagging algorithm [<xref ref-type="bibr" rid="B24">24</xref>] implemented in Haploview version 3.2 [<xref ref-type="bibr" rid="B25">25</xref>]. Minor allele frequency and r<sup>2 </sup>thresholds were set at 0.05 and 0.8, respectively. SNPs selected for each gene are shown in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Association between single nucleotide polymorphisms in leukotriene pathway candidate genes and chronic rhinosinusitis.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene (chr)</bold></td><td align="left"><bold>SNPs</bold></td><td align="center"><bold>MAF</bold></td><td align="center"><bold>Minor allele</bold></td><td align="center"><bold>HWE p value</bold></td><td align="left"><bold>Case, Control Ratios**</bold></td><td align="center"><bold>p value</bold></td></tr></thead><tbody><tr><td align="left">ALOX5AP (13)</td><td align="left">rs12430915</td><td align="center">0.08</td><td align="center">C</td><td align="center">0.200</td><td align="left">38:378, 26:346</td><td align="center">0.271</td></tr><tr><td></td><td align="left">rs4769870</td><td align="center">0.16</td><td align="center">T</td><td align="center">0.080</td><td align="left">353:61, 269:61</td><td align="center">0.170</td></tr><tr><td></td><td align="left">rs4076128</td><td align="center">0.30</td><td align="center">C</td><td align="center">0.439</td><td align="left">290:124, 255:111</td><td align="center">0.909</td></tr><tr><td></td><td align="left">rs11616333</td><td align="center">0.05</td><td align="center">G</td><td align="center">0.558</td><td align="left">22:396, 19:353</td><td align="center">0.922</td></tr><tr><td></td><td align="left">rs4769055</td><td align="center">0.33</td><td align="center">A</td><td align="center">0.187</td><td align="left">143:275, 120:252</td><td align="center">0.561</td></tr><tr><td></td><td align="left">rs9578196</td><td align="center">0.10</td><td align="center">T</td><td align="center">0.408</td><td align="left">380:38, 326:42</td><td align="center">0.283</td></tr><tr><td></td><td align="left">rs4293222</td><td align="center">0.37</td><td align="center">C</td><td align="center">0.930</td><td align="left">161:257, 134:236</td><td align="center">0.505</td></tr><tr><td></td><td align="left">rs12429692</td><td align="center">0.26</td><td align="center">T</td><td align="center">1.000</td><td align="left">118:300, 88:284</td><td align="center">0.144</td></tr><tr><td></td><td align="left">rs10162089</td><td align="center">0.49</td><td align="center">T</td><td align="center">0.828</td><td align="left">217:197, 184:186</td><td align="center">0.453</td></tr><tr><td></td><td align="left">rs4254165</td><td align="center">0.28</td><td align="center">C</td><td align="center">0.928</td><td align="left">302:114, 264:108</td><td align="center">0.612</td></tr><tr><td></td><td align="left">rs4356336</td><td align="center">0.42</td><td align="center">C</td><td align="center">1.000</td><td align="left">242:176, 208:154</td><td align="center">0.902</td></tr><tr><td></td><td align="left">rs17612127</td><td align="center">0.08</td><td align="center">T</td><td align="center">0.847</td><td align="left">40:376, 21:343</td><td align="center"><bold>0.046</bold></td></tr><tr><td></td><td align="left">rs9506352</td><td align="center">0.34</td><td align="center">T</td><td align="center">0.300</td><td align="left">278:138, 242:128</td><td align="center">0.674</td></tr><tr><td></td><td align="left">rs9579648</td><td align="center">0.15</td><td align="center">C</td><td align="center">0.317</td><td align="left">68:350, 52:320</td><td align="center">0.371</td></tr><tr><td></td><td align="left">rs9579649</td><td align="center">0.07</td><td align="center">T</td><td align="center">0.330</td><td align="left">28:388, 24:348</td><td align="center">0.875</td></tr><tr><td></td><td align="left">rs9315051</td><td align="center">0.08</td><td align="center">C</td><td align="center">1.000</td><td align="left">33:385, 26:346</td><td align="center">0.629</td></tr><tr><td></td><td align="left">rs4420371</td><td align="center">0.25</td><td align="center">C</td><td align="center">0.842</td><td align="left">107:311, 93:277</td><td align="center">0.882</td></tr><tr><td></td><td align="left">rs4466940</td><td align="center">0.20</td><td align="center">T</td><td align="center">0.295</td><td align="left">85:329, 60:256</td><td align="center">0.604</td></tr><tr><td></td><td align="left">rs9578200</td><td align="center">0.17</td><td align="center">T</td><td align="center">0.014</td><td align="left">352:66, 307:65</td><td align="center">0.525</td></tr><tr><td></td><td align="left">rs9285076</td><td align="center">0.22</td><td align="center">T</td><td align="center">0.133</td><td align="left">326:92, 289:83</td><td align="center">0.919</td></tr><tr><td></td><td align="left">rs9670198</td><td align="center">0.04</td><td align="center">A</td><td align="center">0.168</td><td align="left">401:15, 329:13</td><td align="center">0.887</td></tr><tr><td></td><td align="left">rs4319601</td><td align="center">0.41</td><td align="center">T</td><td align="center">0.064</td><td align="left">241:163, 209:143</td><td align="center">0.938</td></tr><tr><td></td><td align="left">rs4769063</td><td align="center">0.13</td><td align="center">T</td><td align="center">1.000</td><td align="left">365:51, 322:50</td><td align="center">0.621</td></tr><tr><td></td><td align="left">rs4238139</td><td align="center">0.28</td><td align="center">C</td><td align="center">0.028</td><td align="left">117:301, 99:265</td><td align="center">0.805</td></tr><tr><td align="left">ALOX5 (10)</td><td align="left">rs3824612</td><td align="center">0.38</td><td align="center">T</td><td align="center">0.263</td><td align="left">273:145, 220:152</td><td align="center">0.074</td></tr><tr><td></td><td align="left">rs3780894</td><td align="center">0.17</td><td align="center">C</td><td align="center">0.789</td><td align="left">85:333, 52:320</td><td align="center"><bold>0.019</bold></td></tr><tr><td></td><td align="left">rs7099684</td><td align="center">0.19</td><td align="center">A</td><td align="center">0.456</td><td align="left">82:332, 65:301</td><td align="center">0.466</td></tr><tr><td></td><td align="left">rs7919239</td><td align="center">0.23</td><td align="center">A</td><td align="center">0.392</td><td align="left">101:313, 79:293</td><td align="center">0.293</td></tr><tr><td></td><td align="left">rs2115819</td><td align="center">0.47</td><td align="center">C</td><td align="center">0.414</td><td align="left">195:219, 152:180</td><td align="center">0.720</td></tr><tr><td></td><td align="left">rs11239523</td><td align="center">0.16</td><td align="center">C</td><td align="center">0.831</td><td align="left">71:345, 55:317</td><td align="center">0.383</td></tr><tr><td></td><td align="left">rs4948672</td><td align="center">0.46</td><td align="center">C</td><td align="center">0.512</td><td align="left">203:215, 161:211</td><td align="center">0.137</td></tr><tr><td></td><td align="left">rs12264801</td><td align="center">0.45</td><td align="center">T</td><td align="center">0.028</td><td align="left">230:188, 202:168</td><td align="center">0.904</td></tr><tr><td></td><td align="left">rs3780901</td><td align="center">0.33</td><td align="center">C</td><td align="center">0.440</td><td align="left">143:271, 116:250</td><td align="center">0.400</td></tr><tr><td></td><td align="left">rs2279435</td><td align="center">0.43</td><td align="center">C</td><td align="center">0.707</td><td align="left">187:231, 156:216</td><td align="center">0.428</td></tr><tr><td></td><td align="left">rs1565096</td><td align="center">0.23</td><td align="center">C</td><td align="center">0.094</td><td align="left">323:95, 283:89</td><td align="center">0.691</td></tr><tr><td></td><td align="left">rs1487562</td><td align="center">0.21</td><td align="center">T</td><td align="center">0.381</td><td align="left">97:321, 69:301</td><td align="center">0.117</td></tr><tr><td></td><td align="left">rs2291427</td><td align="center">0.30</td><td align="center">T</td><td align="center">0.870</td><td align="left">298:120, 257:115</td><td align="center">0.498</td></tr><tr><td></td><td align="left">rs7393696</td><td align="center">0.38</td><td align="center">A</td><td align="center">0.394</td><td align="left">256:154, 207:135</td><td align="center">0.591</td></tr><tr><td></td><td align="left">rs7089063</td><td align="center">0.24</td><td align="center">A</td><td align="center">0.478</td><td align="left">112:304, 61:233</td><td align="center">0.059</td></tr><tr><td align="left">CYSLTR2 (13)</td><td align="left">rs2406939</td><td align="center">0.36</td><td align="center">C</td><td align="center">0.948</td><td align="left">152:266, 130:242</td><td align="center">0.678</td></tr><tr><td></td><td align="left">rs11617224</td><td align="center">0.11</td><td align="center">C</td><td align="center">1.000</td><td align="left">375:43, 329:41</td><td align="center">0.719</td></tr><tr><td></td><td align="left">rs6420296</td><td align="center">0.08</td><td align="center">C</td><td align="center">1.000</td><td align="left">389:29, 337:33</td><td align="center">0.303</td></tr><tr><td></td><td align="left">rs7335898</td><td align="center">0.06</td><td align="center">G</td><td align="center">0.790</td><td align="left">28:390, 18:336</td><td align="center">0.345</td></tr><tr><td></td><td align="left">rs9285169</td><td align="center">0.09</td><td align="center">T</td><td align="center">0.136</td><td align="left">43:373, 26:334</td><td align="center">0.129</td></tr><tr><td></td><td align="left">rs9595961</td><td align="center">0.48</td><td align="center">C</td><td align="center">0.994</td><td align="left">203:215, 175:195</td><td align="center">0.722</td></tr><tr><td></td><td align="left">rs17072059</td><td align="center">0.04</td><td align="center">T</td><td align="center">0.784</td><td align="left">407:11, 353:17</td><td align="center">0.137</td></tr><tr><td></td><td align="left">rs7330127</td><td align="center">0.44</td><td align="center">A</td><td align="center">1.000</td><td align="left">189:229, 155:207</td><td align="center">0.501</td></tr><tr><td></td><td align="left">rs2407249</td><td align="center">0.21</td><td align="center">C</td><td align="center">0.129</td><td align="left">88:330, 74:298</td><td align="center">0.687</td></tr><tr><td></td><td align="left">rs9568087</td><td align="center">0.29</td><td align="center">A</td><td align="center">0.315</td><td align="left">299:117, 254:108</td><td align="center">0.600</td></tr><tr><td></td><td align="left">rs12184704</td><td align="center">0.07</td><td align="center">C</td><td align="center">0.057</td><td align="left">33:385, 21:339</td><td align="center">0.259</td></tr><tr><td align="left">CYSLTR1 (X)*</td><td align="left">rs321090</td><td align="center">0.23</td><td align="center">C</td><td align="center">0.605</td><td align="left">247:60, 207:81</td><td align="center"><bold>0.014</bold></td></tr><tr><td></td><td align="left">rs321007</td><td align="center">0.30</td><td align="center">C</td><td align="center">0.916</td><td align="left">224:84, 192:96</td><td align="center">0.107</td></tr><tr><td></td><td align="left">rs321006</td><td align="center">0.13</td><td align="center">T</td><td align="center">0.423</td><td align="left">42:266, 37:252</td><td align="center">0.764</td></tr><tr><td align="left">LTC4S (5)</td><td align="left">rs730012</td><td align="center">0.29</td><td align="center">C</td><td align="center">0.403</td><td align="left">126:292, 103:269</td><td align="center">0.448</td></tr><tr><td></td><td align="left">rs2291418</td><td align="center">0.04</td><td align="center">T</td><td align="center">0.316</td><td align="left">399:15, 347:19</td><td align="center">0.284</td></tr><tr><td></td><td align="left">rs166624</td><td align="center">0.17</td><td align="center">A</td><td align="center">1.000</td><td align="left">77:341, 56:316</td><td align="center">0.207</td></tr></tbody></table><table-wrap-foot><p>HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency.</p><p>*Hardy-Weinberg and association tests were specifically calculated for the X chromosome using the method implemented in Haploview 3.32.</p><p>**Number of allele A observed in cases : number of allele B observed in cases, number of allele A observed in controls : number of allele B observed in controls.</p></table-wrap-foot></table-wrap><p>SNPs were genotyped using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometer (Sequenom, San Diego, CA). Primers were designed using the Sequenom SNP Assay Design software version 3.0 for iPLEX reactions. A total of 59 assays were designed within a 29-, 24- and 7-plexs reactions. The protocol and reaction conditions were in accordance with the manufacturer [<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec><title>Statistical analysis</title><p>Sample size was designed to provide 95% power to detect common alleles (&#x0003e; 10%) conferring a &#x0003e; 3.0 -fold increase in risk, and 50% power to detect alleles &#x0003e;25% that increase risk by a factor of 2.0.</p><p>Hardy-Weinberg equilibrium (HWE) was estimated using a &#x003c7;<sup>2 </sup>test. HWE tests were performed only in females for SNPs located on the X chromosome (SNPs located in the CYSLTR1 gene). Case-control comparisons were analyzed using a &#x003c7;<sup>2 </sup>test implemented in Haploview version 3.2 [<xref ref-type="bibr" rid="B25">25</xref>]. A nominal p-value less than 0.0012 was considered significant. This threshold was computed by permutation testing to ensure a project-wide type 1 error rate of 0.05.</p></sec></sec><sec><title>Results</title><p>210 patients with severe CRS were recruited. Four were not included in the analysis, as phenotypic questionnaires were incomplete. Table <xref ref-type="table" rid="T2">2</xref> shows the characteristics of cases and controls. For cases, initial diagnosis was recurrent rhinosinusitis in 12.1%, CRS without polyposis in 13.1%, and CRS with polyposis in 74.8%. Average number of previous surgeries was 3.15 (range 1 &#x02013; 20; median 2.0), with an average age at first surgery of 38.3 years (range 1 &#x02013; 76; median 38). Medication use in this group was high, with 73.4% of patients requiring medication beyond an inhaled nasal corticosteroid for disease control and 23.3% remaining uncontrolled despite medication. Atopy was present in 65.5% and asthma requiring treatment in 53.9%. Active smoking was present in 11.2%. Patients reported blood relatives affected with CRS in 37.7% of instances.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Characteristics of the subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Cases</bold></td><td align="center"><bold>Controls</bold></td></tr></thead><tbody><tr><td align="left">n</td><td align="center">206</td><td align="center">200</td></tr><tr><td align="left">Age (years)</td><td align="center">52.3 &#x000b1; 13.0</td><td align="center">48.8 &#x000b1; 15.0</td></tr><tr><td align="left">Male: Female ratio</td><td align="center">1.10</td><td align="center">0.79</td></tr><tr><td align="left">Ethnic group (%)</td><td></td><td></td></tr><tr><td align="left">&#x02003;White</td><td align="center">85.2</td><td align="center">89.5</td></tr><tr><td align="left">&#x02003;Middle East</td><td align="center">4.9</td><td align="center">4.4</td></tr><tr><td align="left">&#x02003;Jewish</td><td align="center">5.4</td><td align="center">1.1</td></tr><tr><td align="left">&#x02003;Asian</td><td align="center">1.5</td><td align="center">1.1</td></tr><tr><td align="left">&#x02003;First Nation</td><td align="center">1.5</td><td align="center">0.6</td></tr><tr><td align="left">&#x02003;Black</td><td align="center">1.0</td><td align="center">0.6</td></tr><tr><td align="left">&#x02003;Hispanic</td><td align="center">0.5</td><td align="center">1.1</td></tr><tr><td align="left">&#x02003;Pacific Islander</td><td align="center">0.0</td><td align="center">1.7</td></tr></tbody></table><table-wrap-foot><p>Values are means &#x000b1; SD for age.</p></table-wrap-foot></table-wrap><p>Measured serum biomarkers showed mean circulating eosinophilia of 4.4% (range 0 &#x02013; 25%; median 4.0%) with 33.5% of patients demonstrating &#x0003e; 5% eosinophilia. Mean total serum IgE was 155.9 IU (range 2 &#x02013; 1460, median = 85.0) with 41.1% having levels IgE &#x0003e; 120 IU/ml.</p><sec><title>Genetic analysis</title><p>The assay conversion rate was 95% (56 out of 59) and the average genotyping success rate for the 56 SNPs yielding working assays was 98.7%. The remaining 3 SNPs (rs4503649, rs12561364 and rs1359112) failed the genotyping assay and were discarded from the analyses. All SNPs were in HWE, except rs9578200 where the p-value was 0.014 (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>A final collection of 56 SNPs was tested for association. Figure <xref ref-type="fig" rid="F2">2</xref> illustrates the location of each SNPs relative to the intron-exon structure of each gene. Figure <xref ref-type="fig" rid="F2">2</xref> also depicts the genetic association results between SNPs and CRS. Three SNPs were found to be associated with CRS at a p value &#x0003c; 0.05. These SNPs were found in the ALOX5 (rs3780894), ALOX5AP (rs17612127) and CYSTLR1 (rs321090) genes. However, none of these SNPs reached the multiple testing p value threshold of 0.0012. The linkage disequilibrium pattern for each gene in our population is illustrated in Figure <xref ref-type="fig" rid="F3">3</xref>.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Genetic association of SNPs in the leukotriene pathway genes with chronic rhinosinusitis. Each subfigure presents the result of one gene. The top line indicates the gene name and symbol. The upper part of each subfigure shows the exon-intron structure of the gene and the localization of the genotyped SNPs. The coding exons are shown in black and the untranslated regions are shown in grey. The lower part of each subfigure illustrated the association results for chronic rhinosinusitis. The x-axis shows the localization of the gene and SNPs on build 36. The y-axis shows the p values on a log scale. The lower and upper dash lines represent p value thresholds of 0.05 and 0.0012, respectively. The gene structure for CYSLTR2 was taken from Fukai et al. [38]. The upper and lower parts of each subfigure are shown on the same scale.</p></caption><graphic xlink:href="1471-2350-9-21-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Linkage disequilibrium (LD) plots surrounding genes involved in the leukotriene pathway. The LD plots were generated by Haploview 3.32. [25]. Gene symbols are indicated at the top of each graph. The upper part of each graph illustrated the HapMap info track including the location of the gene on build 34. The white horizontal bar below the info track illustrated the location of SNPs on a physical scale. The color of squares illustrate the strength of pairwise r<sup>2 </sup>values on a black and white scale where black indicates perfect LD (r<sup>2 </sup>= 1.00) and white indicates perfect equilibrium (r<sup>2 </sup>= 0). The r<sup>2 </sup>LD value is also indicated within each square. Blocks are defined using the Gabriel et al. [39] definition. Failed and monomorphic SNPs as well as SNPs not in Hardy-Weinberg equilibrium are not illustrated.</p></caption><graphic xlink:href="1471-2350-9-21-3"/></fig><p>Spurious associations cause by population stratification is always a concern in genetic case-control association studies. Accordingly, the analyses were repeated with only White individuals (162 controls and 173 cases). Globally the results were very similar. All SNPs were in HWE and the minor allele frequencies were practically unchanged compared to all ethnicities included. The SNPs ALOX5-rs3780894 and CYSLTR1-rs321090 remained statistically significant (p = 0.037 and 0.031, respectively). In contrast, SNP ALOX5AP-rs17612127 was no longer significant (p = 0.144).</p></sec></sec><sec><title>Discussion</title><p>In this study, we have analyzed SNPs covering 5 genes implicated in the cysLT pathway in a case-control series of patients with severe CRS. After adjustment of multiple testing, there were no significant associations observed between severe CRS and genetic variants within these genes. Rather than suggest that there is no role for polymorphisms in the leukotriene cascade, it suggests that the effect of polymorphisms in cysLTs is less than the power detectable by our population size, which is well-powered to detect only polymorphisms in common alleles which confer a relative risk (RR) of 3.0 or greater, and only moderately powered to detect polymorphisms with a RR of 2.0. In this study, the minor allele of the most significant polymorphisms conferred a RR of 1.45 (ALOX5-rs3780894), 1.67 (ALOX5AP-rs17612127) and 0.69 (CYSLTR1-rs321090). Most genes for complex diseases that have been described have an effect in this range or less.</p><p>Although SNP CYSLTR1-rs321090 is not significant after multiple testing correction, the results observed in the current study replicated the previous association reported by Hao et al [<xref ref-type="bibr" rid="B27">27</xref>]. In fact, the polymorphism, labeled 927T/C (rs320995) was significantly associated with atopy severity in a group of asthmatic families. Interestingly, this polymorphism is in tight linkage disequilibrium (LD) with rs321090 (r<sup>2 </sup>= 0.82 based on the CEU genotyping dataset of the International HapMap project [<xref ref-type="bibr" rid="B23">23</xref>]). In both studies, the common allele is more frequent in cases than controls. In contrast, the current study does not corroborate the previous association between SNP LTC4S-rs730012 (also known as -444A/C) and allergic rhinitis [<xref ref-type="bibr" rid="B28">28</xref>]. However, a number of controversies exist concerning the role of this polymorphism in allergic-related diseases [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Accordingly, larger and well-powered studies will be required to determine the role of this polymorphism in pathogenesis of these diseases.</p><p>Beside the lack of power, other factors may explain the absence of significant results. First, we have studied what is a relatively heterogeneous population, with several different initial diagnoses, some unresponsive to therapy effective in others and different levels of serum biomarkers of inflammation. It is possible that the effect of cysLTs may be different within these groups and less noticeable in the group as a whole. Analysis of subgroups within our population may be of benefit but will be limited by sample size. Secondly, the control group utilized must also be considered. The group used has been selected for comparability in terms of environment rather than for absence of the disease. With the prevalence of self-reported chronic sinusitis being reported as high a 16% and the incidence of allergies being over 20%, confusion with these other disorders may make it hard to differentiate from these other disorders.</p><p>Leukotrienes have nevertheless been implicated in CRS in other models and several studies have shown that leukotrienes may be involved in the development of the disorder. CysLT metabolites, leukotriene C4 (LTC4), leukotriene D4 (LTD4), and leukotriene E4 (LTE4) likely contribute to the pathogenesis of chronic rhinosinusitis through their effects on microvascular leakage, epithelial cell activation, elevated mucus secretion, and mucosal inflammation [<xref ref-type="bibr" rid="B31">31</xref>]. CysLTs also appear to be related to the severity of eosinophilic inflammation [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>CysLTs appear related to nasal polyposis. In an examination of 27 patients by Kaplan et al. [<xref ref-type="bibr" rid="B33">33</xref>] patients with sinonasal polyps were noted by radioimmunoassay to have elevated levels of LTC4. Patients with sinonasal polyposis with recurrences within 18 months of surgery had higher levels of LTC4 when compared with those patients that did not have recurrences. In another study of 58 individuals, Steinke et al. [<xref ref-type="bibr" rid="B34">34</xref>] reported that chronic hyperplastic eosinophilic sinusitis is characterized by the increased presence of CysLTs when compared with concentrations seen in tissue from patients with chronic inflammatory sinusitis or healthy sinus tissue. Specifically implicating the polyp tissue as the source of these cysLTs, Higashi et al. [<xref ref-type="bibr" rid="B35">35</xref>] found that there were significant decreases in the urinary LTE4 concentrations before and after the sinus surgery for patients with chronic hyperplastic rhinosinusitis with nasal polyposis. In support of this, a recent study showed that urinary LTE4 concentration is highly significant in 10 patients with aspirin-intolerant asthma (AIA) with nasal polyps compare to patients with 24 AIA without polyps [<xref ref-type="bibr" rid="B36">36</xref>].</p><p>Despite the evidence supporting a role for leukotrienes other authors have failed to demonstrate a role for cysLTs in CRS. A study by Kountakis et al [<xref ref-type="bibr" rid="B37">37</xref>] showed that mean cysLTs levels were similar in CRS patients with eosinophilic versus non eosinophilic and in patients with polyps versus without polyp. Also cysLTs levels did not correlate with severity of CRS according to CT findings, endoscopy findings, or symptom scores.</p></sec><sec><title>Conclusion</title><p>While these initial results do not support that polymorphisms in genes assessed involved in the leukotriene pathways are contributing to the pathogenesis of CRS, this initial study was not powered to detect polymorphisms with relative risk of 2.0 or less, where we could expect many gene effects for complex diseases to occur. Thus, despite this lack of significant association noted in this study, we believe that validation with external populations and the use of better-powered studies in the future may allow more conclusive findings.</p></sec><sec><title>List of abbreviations</title><p>AIA: aspirin-intolerant asthma, ALOX5: arachidonate 5-lipoxygenase, ALOX5AP: arachidonate 5-lipoxygenase-activating protein, CF: cystic fibrosis, CRS: Chronic rhinosinusitis, COX: cyclo-oxygenase pathway, CYSLTR1: cysteinyl leukotriene receptor 1, CYSLTR2: cysteinyl leukotriene receptor 2, cysLTs: cysteinyl leukotrienes, HWE: Hardy-Weinberg equilibrium, LD: Linkage disequilibrium, LO: lipoxygenase pathway, LTB4: leukotriene B4, LTC4: leukotriene C4, LTC4S: leukotriene C4 synthase, LTE4: leukotriene E4, RR: relative risk, SNP: single nucleotide polymorphism</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>HAS was involved in sample collection and draft the first version of the manuscript. YB carried out SNP selection and genotyping, performed statistical analyses, and finalized the manuscript. TJH participated in the design of the study. MC, MD, SVS, SF were involved in sample collection and coordination of the case-control population. ML calculated the p-value threshold to ensure a project-wide type 1 error rate of 0.05. MD conceived the study, acquired the funding, and provided general supervision of the research group. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/9/21/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Y. Boss&#x000e9; was recipient of a fellowship award from the Canadian Institutes of Health and Research. T.J. Hudson was the recipient of a Clinician-Scientist Award in Translational Research by the Burroughs Wellcome Fund. Funding was provided by the Fondation Antoine Turmel, the Canadian Institutes of Health Research and the McGill Otolaryngology Head and Neck Surgery Research Fund.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gliklich</surname><given-names>RE</given-names></name><name><surname>Metson</surname><given-names>R</given-names></name></person-group><article-title>The health impact of chronic sinusitis in patients seeking otolaryngologic care</article-title><source>Otolaryngol Head Neck Surg</source><year>1995</year><volume>113</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">7603703</pub-id><pub-id pub-id-type="doi">10.1016/S0194-5998(95)70152-4</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Hormann</surname><given-names>K</given-names></name><name><surname>Mosges</surname><given-names>R</given-names></name><name><surname>Rasp</surname><given-names>G</given-names></name><name><surname>Riechelmann</surname><given-names>H</given-names></name><name><surname>Muller</surname><given-names>R</given-names></name><name><surname>Luckhaupt</surname><given-names>H</given-names></name><name><surname>Stuck</surname><given-names>BA</given-names></name><name><surname>Rudack</surname><given-names>C</given-names></name></person-group><article-title>An update on the diagnosis and treatment of sinusitis and nasal polyposis</article-title><source>Allergy</source><year>2003</year><volume>58</volume><fpage>176</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">12653791</pub-id><pub-id pub-id-type="doi">10.1034/j.1398-9995.2003.02172.x</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Fishman</surname><given-names>P</given-names></name><name><surname>Short</surname><given-names>SO</given-names></name><name><surname>Sullivan</surname><given-names>SD</given-names></name><name><surname>Yueh</surname><given-names>B</given-names></name><name><surname>Weymuller</surname><given-names>EA</given-names><suffix>Jr</suffix></name></person-group><article-title>Health care utilization and cost among adults with chronic rhinosinusitis enrolled in a health maintenance organization</article-title><source>Otolaryngol Head Neck Surg</source><year>2002</year><volume>127</volume><fpage>367</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">12447229</pub-id><pub-id pub-id-type="doi">10.1067/mhn.2002.129815</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desrosiers</surname><given-names>M</given-names></name></person-group><article-title>Refractory chronic rhinosinusitis: pathophysiology and management of chronic rhinosinusitis persisting after endoscopic sinus surgery</article-title><source>Current allergy and asthma reports</source><year>2004</year><volume>4</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">15056402</pub-id><pub-id pub-id-type="doi">10.1007/s11882-004-0027-z</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terwilliger</surname><given-names>JD</given-names></name><name><surname>Goring</surname><given-names>HH</given-names></name></person-group><article-title>Gene mapping in the 20th and 21st centuries: statistical methods, data analysis, and experimental design</article-title><source>Human biology; an international record of research</source><year>2000</year><volume>72</volume><fpage>63</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">10721614</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>NA</given-names></name><name><surname>Widelitz</surname><given-names>JS</given-names></name><name><surname>Chiu</surname><given-names>AG</given-names></name><name><surname>Palmer</surname><given-names>JN</given-names></name><name><surname>Kennedy</surname><given-names>DW</given-names></name></person-group><article-title>Familial aggregation of sinonasal polyps correlates with severity of disease</article-title><source>Otolaryngol Head Neck Surg</source><year>2006</year><volume>134</volume><fpage>601</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">16564380</pub-id><pub-id pub-id-type="doi">10.1016/j.otohns.2005.11.042</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drake-Lee</surname><given-names>A</given-names></name></person-group><article-title>Nasal polyps in identical twins</article-title><source>The Journal of Laryngology and Otology</source><year>1992</year><volume>106</volume><fpage>1084</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">1487667</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greisner</surname><given-names>WA</given-names><suffix>3rd</suffix></name><name><surname>Settipane</surname><given-names>GA</given-names></name></person-group><article-title>Hereditary factor for nasal polyps</article-title><source>Allergy Asthma Proc</source><year>1996</year><volume>17</volume><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">8922148</pub-id><pub-id pub-id-type="doi">10.2500/108854196778662192</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaliner</surname><given-names>MA</given-names></name><name><surname>Osguthorpe</surname><given-names>JD</given-names></name><name><surname>Fireman</surname><given-names>P</given-names></name><name><surname>Anon</surname><given-names>J</given-names></name><name><surname>Georgitis</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>ML</given-names></name><name><surname>Naclerio</surname><given-names>R</given-names></name><name><surname>Kennedy</surname><given-names>D</given-names></name></person-group><article-title>Sinusitis: bench to bedside. Current findings, future directions</article-title><source>The Journal of Allergy and Clinical Immunology</source><year>1997</year><volume>99</volume><fpage>S829</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">9212027</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>SH</given-names></name><name><surname>Li</surname><given-names>TY</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>JB</given-names></name><name><surname>Wen</surname><given-names>WP</given-names></name><name><surname>Wen</surname><given-names>WH</given-names></name></person-group><article-title>[Genetic epidemiologic study on nasal polyps]</article-title><source>Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (Chinese Journal of Otorhinolaryngology Head and Neck Surgery)</source><year>2007</year><volume>42</volume><fpage>608</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">17944211</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fajardo-Dolci</surname><given-names>G</given-names></name><name><surname>Solorio-Abreu</surname><given-names>J</given-names></name><name><surname>Romero-Alvarez</surname><given-names>JC</given-names></name><name><surname>Zavaleta-Villa</surname><given-names>B</given-names></name><name><surname>Cerezo-Camacho</surname><given-names>O</given-names></name><name><surname>Jimenez-Lucio</surname><given-names>R</given-names></name><name><surname>Olivo-Diaz</surname><given-names>A</given-names></name></person-group><article-title>DQA1 and DQB1 association and nasal polyposis</article-title><source>Otolaryngol Head Neck Surg</source><year>2006</year><volume>135</volume><fpage>243</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">16890076</pub-id><pub-id pub-id-type="doi">10.1016/j.otohns.2006.03.034</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luxenberger</surname><given-names>W</given-names></name><name><surname>Posch</surname><given-names>U</given-names></name><name><surname>Berghold</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>T</given-names></name><name><surname>Lang-Loidolt</surname><given-names>D</given-names></name></person-group><article-title>HLA patterns in patients with nasal polyposis</article-title><source>Eur Arch Otorhinolaryngol</source><year>2000</year><volume>257</volume><fpage>137</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">10839486</pub-id><pub-id pub-id-type="doi">10.1007/s004050050210</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molnar-Gabor</surname><given-names>E</given-names></name><name><surname>Endreffy</surname><given-names>E</given-names></name><name><surname>Rozsasi</surname><given-names>A</given-names></name></person-group><article-title>HLA-DRB1, -DQA1, and -DQB1 genotypes in patients with nasal polyposis</article-title><source>The Laryngoscope</source><year>2000</year><volume>110</volume><fpage>422</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">10718431</pub-id><pub-id pub-id-type="doi">10.1097/00005537-200003000-00017</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Polymorphism between loci for human leukocyte antigens DR and DQ in patients with nasal polyps</article-title><source>The Annals of otology, rhinology, and laryngology</source><year>2007</year><volume>116</volume><fpage>66</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17305280</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Moylan</surname><given-names>B</given-names></name><name><surname>Leopold</surname><given-names>DA</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Rubenstein</surname><given-names>RC</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Proud</surname><given-names>D</given-names></name><name><surname>Zeitlin</surname><given-names>PL</given-names></name><name><surname>Cutting</surname><given-names>GR</given-names></name></person-group><article-title>Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population</article-title><source>Jama</source><year>2000</year><volume>284</volume><fpage>1814</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">11025834</pub-id><pub-id pub-id-type="doi">10.1001/jama.284.14.1814</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Majima</surname><given-names>Y</given-names></name><name><surname>Sakakura</surname><given-names>Y</given-names></name></person-group><article-title>Tumor necrosis factor gene polymorphism in chronic sinusitis</article-title><source>The Laryngoscope</source><year>2000</year><volume>110</volume><fpage>1711</fpage><lpage>1714</lpage><pub-id pub-id-type="pmid">11037831</pub-id><pub-id pub-id-type="doi">10.1097/00005537-200010000-00027</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name><name><surname>Shin</surname><given-names>HD</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name></person-group><article-title>Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">16916603</pub-id><pub-id pub-id-type="doi">10.1016/j.rmed.2006.07.002</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>YK</given-names></name><name><surname>Lin</surname><given-names>CD</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>Hwang</surname><given-names>GY</given-names></name><name><surname>Tsai</surname><given-names>SW</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Tsai</surname><given-names>MH</given-names></name><name><surname>Tsai</surname><given-names>JJ</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name></person-group><article-title>Increased prevalence of interleukin-1 receptor antagonist gene polymorphism in patients with chronic rhinosinusitis</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>2006</year><volume>132</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">16549749</pub-id><pub-id pub-id-type="doi">10.1001/archotol.132.3.285</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bussu</surname><given-names>F</given-names></name><name><surname>Tiziano</surname><given-names>FD</given-names></name><name><surname>Giorgio</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>AM</given-names></name><name><surname>De Corso</surname><given-names>E</given-names></name><name><surname>Angelozzi</surname><given-names>C</given-names></name><name><surname>Brahe</surname><given-names>C</given-names></name><name><surname>Paludetti</surname><given-names>G</given-names></name></person-group><article-title>Argl6gly polymorphism of the beta2-adrenoceptor gene (ADRBeta2) as a susceptibility factor for nasal polyposis</article-title><source>American journal of rhinology</source><year>2007</year><volume>21</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">17621827</pub-id><pub-id pub-id-type="doi">10.2500/ajr.2007.21.3015</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanaoka</surname><given-names>Y</given-names></name><name><surname>Boyce</surname><given-names>JA</given-names></name></person-group><article-title>Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>1503</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">15265876</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Foegh</surname><given-names>ML</given-names></name><name><surname>Hecker</surname><given-names>M</given-names></name><name><surname>Ramwell</surname><given-names>PW</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Katzung BG</surname></name></person-group><article-title>The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds</article-title><source>Basic and clinical pharmacology</source><year>1998</year><edition>5</edition><publisher-name>Connecticut: Appleton and Lange</publisher-name><fpage>304</fpage><lpage>318</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>EO</given-names></name><name><surname>Hamilos</surname><given-names>DL</given-names></name><name><surname>Hadley</surname><given-names>JA</given-names></name><name><surname>Lanza</surname><given-names>DC</given-names></name><name><surname>Marple</surname><given-names>BF</given-names></name><name><surname>Nicklas</surname><given-names>RA</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Baraniuk</surname><given-names>J</given-names></name><name><surname>Baroody</surname><given-names>FM</given-names></name><name><surname>Benninger</surname><given-names>MS</given-names></name><name><surname>Brook</surname><given-names>I</given-names></name><name><surname>Chowdhury</surname><given-names>BA</given-names></name><name><surname>Druce</surname><given-names>HM</given-names></name><name><surname>Durham</surname><given-names>S</given-names></name><name><surname>Ferguson</surname><given-names>B</given-names></name><name><surname>Gwaltney</surname><given-names>JM</given-names><suffix>Jr</suffix></name><name><surname>Kaliner</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>DW</given-names></name><name><surname>Lund</surname><given-names>V</given-names></name><name><surname>Naclerio</surname><given-names>R</given-names></name><name><surname>Pawankar</surname><given-names>R</given-names></name><name><surname>Piccirillo</surname><given-names>JF</given-names></name><name><surname>Rohane</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Slavin</surname><given-names>RG</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name><name><surname>Wald</surname><given-names>ER</given-names></name><name><surname>Zinreich</surname><given-names>SJ</given-names></name></person-group><article-title>Rhinosinusitis: Establishing definitions for clinical research and patient care</article-title><source>Otolaryngol Head Neck Surg</source><year>2004</year><volume>131</volume><fpage>S1</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15577816</pub-id><pub-id pub-id-type="doi">10.1016/j.otohns.2004.09.067</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><article-title>A haplotype map of the human genome</article-title><source>Nature</source><year>2005</year><volume>437</volume><fpage>1299</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">16255080</pub-id><pub-id pub-id-type="doi">10.1038/nature04226</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><name><surname>Pe'er</surname><given-names>I</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>Efficiency and power in genetic association studies</article-title><source>Nature genetics</source><year>2005</year><volume>37</volume><fpage>1217</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">16244653</pub-id><pub-id pub-id-type="doi">10.1038/ng1669</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics (Oxford, England)</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id></citation></ref><ref id="B26"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Oeth</surname><given-names>P</given-names></name><name><surname>Beaulieu</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Kosman</surname><given-names>D</given-names></name><name><surname>del Mistro</surname><given-names>G</given-names></name><name><surname>van den Boom</surname><given-names>D</given-names></name><name><surname>Jurinke</surname><given-names>C</given-names></name></person-group><article-title>iPLEX assay: Increased plexing efficiency and flexibility for MassArray system through single base primer extension with mass-modified terminators</article-title><source>SEQUENOM Application Note</source><year>2005</year></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Sayers</surname><given-names>I</given-names></name><name><surname>Cakebread</surname><given-names>JA</given-names></name><name><surname>Barton</surname><given-names>SJ</given-names></name><name><surname>Beghe</surname><given-names>B</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Sampson</surname><given-names>AP</given-names></name><name><surname>Holloway</surname><given-names>JW</given-names></name></person-group><article-title>The cysteinyl-leukotriene type 1 receptor polymorphism 927T/C is associated with atopy severity but not with asthma</article-title><source>Clin Exp Allergy</source><year>2006</year><volume>36</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">16776674</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2222.2006.02511.x</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eskandari</surname><given-names>HG</given-names></name><name><surname>Unal</surname><given-names>M</given-names></name><name><surname>Ozturk</surname><given-names>OG</given-names></name><name><surname>Vayisoglu</surname><given-names>Y</given-names></name><name><surname>Muslu</surname><given-names>N</given-names></name></person-group><article-title>Leukotriene C4 synthase A-444C gene polymorphism in patients with allergic rhinitis</article-title><source>Otolaryngol Head Neck Surg</source><year>2006</year><volume>134</volume><fpage>997</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">16730545</pub-id><pub-id pub-id-type="doi">10.1016/j.otohns.2006.02.007</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isidoro-Garcia</surname><given-names>M</given-names></name><name><surname>Davila</surname><given-names>I</given-names></name><name><surname>Moreno</surname><given-names>E</given-names></name><name><surname>Lorente</surname><given-names>F</given-names></name><name><surname>Gonzalez-Sarmiento</surname><given-names>R</given-names></name></person-group><article-title>Analysis of the leukotriene C4 synthase A-444C promoter polymorphism in a Spanish population</article-title><source>The Journal of allergy and clinical immunology</source><year>2005</year><volume>115</volume><fpage>206</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">15637574</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2004.08.033</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kedda</surname><given-names>MA</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Phelps</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>I</given-names></name><name><surname>O'Hara</surname><given-names>K</given-names></name><name><surname>Fong</surname><given-names>K</given-names></name><name><surname>Thompson</surname><given-names>PJ</given-names></name></person-group><article-title>Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma</article-title><source>The Journal of allergy and clinical immunology</source><year>2004</year><volume>113</volume><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">15131571</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2004.02.008</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Takeno</surname><given-names>S</given-names></name><name><surname>Furukido</surname><given-names>K</given-names></name><name><surname>Hirakawa</surname><given-names>K</given-names></name><name><surname>Yajin</surname><given-names>K</given-names></name></person-group><article-title>Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis</article-title><source>The Annals of otology, rhinology, and laryngology</source><year>2003</year><volume>112</volume><fpage>955</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">14653364</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez-Novo</surname><given-names>CA</given-names></name><name><surname>Watelet</surname><given-names>JB</given-names></name><name><surname>Claeys</surname><given-names>C</given-names></name><name><surname>Van Cauwenberge</surname><given-names>P</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name></person-group><article-title>Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis</article-title><source>The Journal of allergy and clinical immunology</source><year>2005</year><volume>115</volume><fpage>1189</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">15940133</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2005.02.029</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klapan</surname><given-names>I</given-names></name><name><surname>Culo</surname><given-names>F</given-names></name><name><surname>Culig</surname><given-names>J</given-names></name><name><surname>Bukovec</surname><given-names>Z</given-names></name><name><surname>Simovic</surname><given-names>S</given-names></name><name><surname>Viseslav</surname><given-names>C</given-names></name><name><surname>Risavi</surname><given-names>R</given-names></name><name><surname>Zeljko</surname><given-names>B</given-names></name><name><surname>Sprem</surname><given-names>N</given-names></name><name><surname>Miljenko</surname><given-names>V</given-names></name></person-group><article-title>Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value</article-title><source>American journal of otolaryngology</source><year>1995</year><volume>16</volume><fpage>396</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">8572256</pub-id><pub-id pub-id-type="doi">10.1016/0196-0709(95)90077-2</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinke</surname><given-names>JW</given-names></name><name><surname>Bradley</surname><given-names>D</given-names></name><name><surname>Arango</surname><given-names>P</given-names></name><name><surname>Crouse</surname><given-names>CD</given-names></name><name><surname>Frierson</surname><given-names>H</given-names></name><name><surname>Kountakis</surname><given-names>SE</given-names></name><name><surname>Kraft</surname><given-names>M</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma</article-title><source>The Journal of allergy and clinical immunology</source><year>2003</year><volume>111</volume><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">12589355</pub-id><pub-id pub-id-type="doi">10.1067/mai.2003.67</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname><given-names>N</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Mita</surname><given-names>H</given-names></name><name><surname>Kawagishi</surname><given-names>Y</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Higashi</surname><given-names>A</given-names></name><name><surname>Osame</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>K</given-names></name></person-group><article-title>Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis</article-title><source>The Journal of allergy and clinical immunology</source><year>2004</year><volume>113</volume><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">14767442</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2003.10.068</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Micheletto</surname><given-names>C</given-names></name><name><surname>Visconti</surname><given-names>M</given-names></name><name><surname>Tognella</surname><given-names>S</given-names></name><name><surname>Facchini</surname><given-names>FM</given-names></name><name><surname>Dal Negro</surname><given-names>RW</given-names></name></person-group><article-title>Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls</article-title><source>Allergie et Immunologie</source><year>2006</year><volume>38</volume><fpage>20</fpage><lpage>23</lpage></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kountakis</surname><given-names>SE</given-names></name><name><surname>Arango</surname><given-names>P</given-names></name><name><surname>Bradley</surname><given-names>D</given-names></name><name><surname>Wade</surname><given-names>ZK</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Molecular and cellular staging for the severity of chronic rhinosinusitis</article-title><source>The Laryngoscope</source><year>2004</year><volume>114</volume><fpage>1895</fpage><lpage>1905</lpage><pub-id pub-id-type="pmid">15510011</pub-id><pub-id pub-id-type="doi">10.1097/01.mlg.0000147917.43615.c0</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukai</surname><given-names>H</given-names></name><name><surname>Ogasawara</surname><given-names>Y</given-names></name><name><surname>Migita</surname><given-names>O</given-names></name><name><surname>Koga</surname><given-names>M</given-names></name><name><surname>Ichikawa</surname><given-names>K</given-names></name><name><surname>Shibasaki</surname><given-names>M</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>E</given-names></name></person-group><article-title>Association between a polymorphism in cysteinyl leukotriene receptor 2 on chromosome 13q14 and atopic asthma</article-title><source>Pharmacogenetics</source><year>2004</year><volume>14</volume><fpage>683</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">15454733</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200410000-00006</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>JM</given-names></name><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Blumenstiel</surname><given-names>B</given-names></name><name><surname>Higgins</surname><given-names>J</given-names></name><name><surname>DeFelice</surname><given-names>M</given-names></name><name><surname>Lochner</surname><given-names>A</given-names></name><name><surname>Faggart</surname><given-names>M</given-names></name><name><surname>Liu-Cordero</surname><given-names>SN</given-names></name><name><surname>Rotimi</surname><given-names>C</given-names></name><name><surname>Adeyemo</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>R</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>The structure of haplotype blocks in the human genome</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>2225</fpage><lpage>2229</lpage><pub-id pub-id-type="pmid">12029063</pub-id><pub-id pub-id-type="doi">10.1126/science.1069424</pub-id></citation></ref></ref-list></back></article> 